Abstract
Lower urinary tract dysfunction is one of the challenging problems facing urologists and patients. Several treatment trials have been introduced in the literature, but none has proven to be as effective as being a gold standard treatment for such conditions. We reviewed the literature regarding the use of botulinum toxin (BTx) type A as a current treatment of lower urinary tract conditions described below. The toxin has been shown to be safe and effective in the treatment of conditions caused by increased muscle tonicity. Indications for the urological use of BTx and future applications are also considered.
Similar content being viewed by others
References
Verhayden J, Blitzer A, Brin MF (2001) Other non cosmetic uses of Botox. Semin Cutan Med Surg 20(2):121–126
Neumann M, Wolfgang HJ, Toyka KV (1999) Botulinum toxin in the treatment of neurological disorders of the autonomic nervous system. Arch Neurol 56:914–916
Leippold T, Reitz A, Schurch B (2003) Botulinum toxin as a new therapy option for voiding disorders: current state of the art. Eur Urol 44:165–174
Divakara Kedlaya et al (2002) Botulinum toxin: overview. eMedicine (January 2002)
www.bnf.org
Schurch B (1998) Letters to the Editor—botulinum toxin in SCI. Arch Phys Med Rehabil 79:1481
Barnes M (2003) Botulinum toxin—mechanisms of action and clinical use in spasticity. J Rehab Med 41(Suppl):56–59
Cannon TW, Chancellor MB (2002) Pharmacotherapy of the overactive bladder and advances in drug delivery. Clin Obstet Gynaecol 45(1):205–217
Wheller JS Jr, Walter JS, Chintam RS et al (1988) Botulinum toxin injections for voiding dysfunction following SCI. J Spinal Cord Med 21:227–229
Duchen LW (1970) Changes in motor innervation and cholinesterase localization induced by botulinum toxin in skeletal muscle of the mouse: differences between fast and slow muscles. J Neurol Neurosurg Psychiatry 33:40
Borodic GE, Joseph M, Fay L et al (1990) Botulinum toxin for the treatment of spasmodic torticollis: dysphagia and regional toxin spread. Head Neck 12:392
Lazzeri M (2003) New pharmacological tools. Urodynamica 13:67–73
Nolan J, Chalkiadis GA, Low J et al (2000) Anaesthesia and pain management in cerebral palsy. Anaesthesia 55:32–41
Schurch B, Hauri D, Rodic B (1996) Botulinum-A toxin as a treatment of detrusor-sphincter dyssynergia: a prospective study in 24 spinal cord injury patients. J Urol 155:1023–1029
Deseze M, Petit H, Gallien P et al (2002) Botulinum A toxin and detrusor sphincter dyssynergia: a double blind lidocaine controlled study in 13 patients with spinal cord disease. Eur Urol 42:56–62
Phelan MW, Franks M, Somoyogi GT et al (2001) Botulinum toxin urethral sphincter injection to restore bladder emptying in men and women with voiding dysfunction. J Urol 165:1107–1110
Gallien P, Robineau S, Verin M et al (1998) Treatment of detrusor sphincter dyssynergia by transperineal injection of botulinum toxin. Arch Phys Med Rehabil 79:715–717
Plevnik S, Janez J (1979) Maximal electrical stimulation for urinary incontinence: report of 98 cases. Urology 14(6):638–645
Litwiller SE, Frohman EM, Zimmern P (1999) Multiple sclerosis and the urologist. J Urol 161:743–757
Schurch B, Stohrer M, Kramer D (2000) Botulinum A toxin for treating detrusor hyperreflaxia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 164:692–697
Schulte-Baukloh H, Michael T, Schobert J (2002) Efficacy of botulinum A toxin in children with detrusor hyperreflexia due to myelomeningocele: preliminary results. Urology 59(3):325–328
Elliot DS, Boone TB (2000) Recent advances in the management of the neurogenic bladder. Urology 56(Suppl 6A):76–81
Kuo HC (2004 May) Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents. J Urol 63(5):868–872
Reitz A, Von Tobel J et al (2002) European experience of 184 cases treated with botulinum-A toxin injections into the detrusor muscle for neurogenic incontinence. Neurol Urodyn 21:427–428
Reitz A, Stohrer M, Kramer G et al (2004) European experience of 200 cases treated with botulinum-A toxin injections into the detrusor muscle for urinary incontinence due to neurogenic detrusor overactivity. Eur Urol 45(4):510–515, April
Maria G, Destitio A, Lacquanti S (1998) Relief by botulinum toxin of voiding dysfunction due to prostatitis. Lancet 352:625
Zermann DH, Ishigooka M, Doggweiller-Wiygul R et al (2000) Perisphincteric injection of botulinum toxin type A. A treatment option in patients with chronic prostatic pain? Eur Urol 38(4):393–399
Kuo H (2003) Effect of botulinum A toxin in the treatment of voiding dysfunction due to detrusor underactivity. Urology 61(3):550–554
Fowler CF, Betts CD, Christmas TJ et al (1992) Botulinum toxin in the treatment of chronic urinary retention in women. Br J Urol 70:387–389
Giannantoni A, Mearnini E, Di Stasi SM et al (2004) New therapeutic options for refractory neurogenic detrusor overactivity. Minerva Urol Nefrol 56(1):79–87, March